Reuters logo
BRIEF-Spring Bank Pharma provides positive mid-stage data on Hep B drug
May 23, 2017 / 8:17 PM / 4 months ago

BRIEF-Spring Bank Pharma provides positive mid-stage data on Hep B drug

May 23 (Reuters) - Spring Bank Pharmaceuticals Inc

* Spring bank pharmaceuticals announces top-line results from the initial cohort of the phase 2a segment of the achieve trial, a global phase 2 clinical trial for chronic hepatitis b virus (hbv)

* Spring bank - sb 9200 shows favorable safety profile and antiviral activity against hbv dna and hbsag with initial low dose monotherapy of 25mg

* Spring bank pharmaceuticals inc - overall safety profile of sb 9200 was favorable, and over 12-week study, no serious adverse events were observed Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below